#Genentech

SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies SanegeneBio has entered into a significant global partnership with Genentech to develop RNAi therapeutics, receiving $200 million upfront and potential earnings up to $1.5 billion.

1 month ago

SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies #United_States #Boston #Genentech #RNAi_Therapeutics #SanegeneBio

0 0 0 0

Emil Lazzaroni

@globalcompounders.bsky.social

1 month ago

38. We understand disease and treat it For our thirty-eighth episode, we're exploring a company that has been at the forefront of the fight against cancer for decades. A company that built its empire on a unique, two-pillar strategy that is perfectly suited for the future of healthcare. They don't just want to sell you the cure; they want to sell the test that tells you if the cure will work. It’s a story of visionary acquisitions and world-class science. We are talking about the Swiss giant... Roche. When you hear the name Roche ($RHHBY), you think of a global pharmaceutical powerhouse, a Swiss giant renowned for its leadership in developing cancer treatments. For decades, it has been a defensive cornerstone in portfolios, known for its deep scientific expertise and a vast portfolio of life-saving medicines. But the real story and strategic advantage of Roche lie in its unique dual structure. It is a world leader in not just pharmaceuticals but also in-vitro diagnostics. This powerful combination allows Roche to champion "personalized healthcare"—they can develop a diagnostic test to identify which patients will benefit most from a specific drug, and then provide that targeted therapy. This integrated model creates a formidable competitive moat. However, like all pharma giants, Roche is in a constant race against the patent cliff, with blockbuster drugs facing biosimilar competition. We're analyzing the data to see if Roche's synergistic approach and powerful R&D pipeline are enough to outrun patent expirations and diagnose a healthy future for investors.

📣 New Podcast! "38. We understand disease and treat it" on @Spreaker #biotech #defensive #diagnostics #dividend #drugs #finance #genentech #healthcare #innovation #investing #oncology #patents #personalized #pharma #pipeline #portfolio #rhhby #roche #stock #swiss

2 0 0 0

Fortune Turkey

@fortuneturkey.bsky.social

1 month ago

2) .. inşaat alanlarında 2 binden fazla doğrudan istihdam yaratılması bekleniyor. Yatırım, Genentech’in yeni nesil metabolik tedaviler üretme kapasitesini artırmayı ve Roche’un ABD’deki uzun vadeli üretim stratejisini güçlendirmeyi amaçlıyor. #roche #genentech

0 0 0 0

Hanna Lemmik

@hlemmik.bsky.social

1 month ago

We're no longer alone! A few months after our preprint, another study appeared from #Genentech reporting no MRI brain volume or behaviour differences in adult C3aR1 KOs + their data contradicts another accepted C3aR1 neuroinflammation phenotype. Check it out: www.biorxiv.org/content/10.1...

4 0 1 0

Consortium for Top-Down Proteomics

@proteoforms.bsky.social

1 month ago

NEW WORKSHOP "Top-Down, Intact, and Native Mass Spectrometry in Biopharmaceutical Characterization" Feb.12, 2026. Speakers from #AstraZeneca, #Novartis, #Pfizer, #Genentech, #Sanofi, #JnJ, #Lilly and #NIBRT share stories and perspectives. > ctdp.org/biopharma-wo... #ADCs #mAbs #BsAbs #TsAbs #AAVs

2 1 0 0

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

2 months ago

As year-end nears, pharma groups plump up their pipelines Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

#BristolMyersSquibb #Sanofi #Pfizer #Roche #YarrowBioscience #RandDpipelines #HarbourBioMed #Genentech #AI #CarisLifeSciences #CarisDiscovery #ADEL #phase1testing #DrenBio #drugdiscovery #immunology #oncology #rheumatology #Gravesdisease #GeneSciencePharma #GenSci
zurl.co/Kyjjn

0 0 0 0

OncoDaily

@oncodaily.bsky.social

2 months ago

Caris Discovery Entered Into a Multi-Year Collaboration and License Agreement with Genentech - OncoDaily Caris Discovery Entered Into a Multi-Year Collaboration and License Agreement with Genentech / Brian J. Brille, cancer, Caris Discovery, Caris Life Sciences,

Caris Discovery Entered Into a Multi-Year Collaboration and License Agreement with Genentech

oncodaily.com/voices/caris...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CarisDiscovery #Genentech

3 0 0 0

Caris Life Sciences Teams Up with Genentech for Cancer Research Breakthroughs Caris Life Sciences has partnered with Genentech to explore new cancer treatment targets, aiming to enhance precision medicine and address unmet clinical needs.

2 months ago

Caris Life Sciences Teams Up with Genentech for Cancer Research Breakthroughs #United_States #Cancer_Research #Caris_Life_Sciences #Irving #Genentech

0 0 0 0

Genentech: Press Releases | Monday, Dec 8, 2025 Discover the latest news about our company, our products, our policies, and our people.

3 months ago

⚡️ #Genentech présente des données de #Lunsumio montrant un potentiel dans les #Lymphomes 🩸 indolents et agressifs.

Le Lunsumio avec la #Lénalidomide 💊, offre un traitement efficace pour le lymphome folliculaire R/R, basé l’étude de phase III #CELESTIMO

www.gene.com/media/press-...

0 0 0 0

@pharmalot.bsky.social

3 months ago

Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Up and Down the Ladder: Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #Gilead #Genentech

0 0 0 0

Genentech: Press Releases | Monday, Nov 17, 2025 Discover the latest news about our company, our products, our policies, and our people.

3 months ago

🔴 #Breaking : #Giredestrant 🧬 de #Genentech devient la première #SERD orale à montrer une survie invasive sans maladie supérieure dans le #CancerDuSein précoce.

👉 Résultats positifs de phase III de l’étude #LidERA

#BreastCancer 🦀 #ESMO25
www.gene.com/media/press-...

1 0 0 0

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

4 months ago

34-35 PHARMA - Time capsule Time capsule. The ten groundbreaking drugs shaping 2025 and the future

#Vertex #Cysticfibrosis #AstraZeneca #DaiichiSankyo #lungcancer #breastcancer #painmanagement #Alnylam #Sanofi #Haemophilia #Genentech #Roche #MS #MSD #Hypercholesterolemia #Pfizer #InnoventBiologics #EliLilly #Obesity #type2diabetes #GSK #eosinophilicasthma #meningitisvaccine
zurl.co/bzBzK

2 0 0 0

Surag Nair

@suragnair.bsky.social

4 months ago

Nona: A unifying multimodal masking framework for functional genomics The non-coding genome encodes complex regulatory logic that orchestrates gene expression and cell identity. While machine learning models for functional genomics have advanced our understanding of the...

This would not have been possible without my amazing colleagues from BRAID #Genentech: Gökcen Ehsan Alex @johahi.bsky.social Nate @avantikalal.bsky.social Tommaso Hector Gabriele

You can find the preprint here: www.biorxiv.org/content/10.1...

12/

1 0 1 0

Genentech: Press Releases | Sunday, Nov 9, 2025 Discover the latest news about our company, our products, our policies, and our people.

4 months ago

Le #Fénébrutinib de #Genentech montre des résultats positifs sans précédent en phase III en tant que premier et seul inhibiteur potentiel de la #BTK dans la #ScléroseEnPlaques ( #RMS) progressive récurrente et primaire
www.gene.com/media/press-...

1 0 0 0

scverse

@scverse.bsky.social

4 months ago

Meet the keynote speakers for the 2025 scverse conference!

John Marioni, Head of Computation at Genentech Research and Early Development and former head of EBI
🧵

#scverse #scverse2025 #AI #DrugDevelopment #MachineLearning #ComputationalBiology #Biotech #Pharma #Genentech

4 1 1 0

scverse

@scverse.bsky.social

4 months ago

🌟 Thank You to Our Gold Sponsor: Genentech! 🌟

We're delighted to recognize Genentech as a Gold Sponsor of scverse conference 2025! 🏆

#scverse2025 #ComputationalBiology #SingleCell #DrugDiscovery #Genentech #SpatialOmics #Bioinformatics #Biotechnology

1 0 1 1

FDA Greenlights Gazyva® for Lupus Nephritis Treatment: A Major Step Forward The FDA has approved Gazyva® for lupus nephritis in adults, illustrating an important advancement in treatment options against this debilitating condition.

4 months ago

FDA Greenlights Gazyva® for Lupus Nephritis Treatment: A Major Step Forward #USA #Washington #Lupus_Nephritis #Genentech #GAZYVA

0 0 0 0

Lupus Research Alliance Celebrates FDA Approval of Gazyva for Lupus Nephritis Treatment The Lupus Research Alliance expresses gratitude for the FDA's approval of Gazyva, marking a significant advancement in lupus nephritis management.

4 months ago

Lupus Research Alliance Celebrates FDA Approval of Gazyva for Lupus Nephritis Treatment #USA #New_York #Lupus_Nephritis #Genentech #GAZYVA

1 0 0 0

Sally G Pasion

@sgpombe.bsky.social

4 months ago

Welcome prospective #SFSU students to DISCOVER SFSU!!! We are so happy to have you join us!! A shout out to @sfstatebio.bsky.social alumna #Leslie_Valencia #Genentech being highlighted in today’s program!👏🏽👏🏽👏🏽 @calstate.bsky.social #SFSU_COSE

2 0 0 0